Last reviewed · How we verify

Micardis plus 80/12.5

Heart Care Foundation · FDA-approved active Small molecule

Micardis plus 80/12.5 is a Angiotensin II receptor blocker + thiazide diuretic combination Small molecule drug developed by Heart Care Foundation. It is currently FDA-approved for Hypertension (essential hypertension in patients requiring combination therapy).

Micardis Plus combines telmisartan (an angiotensin II receptor blocker) with hydrochlorothiazide (a thiazide diuretic) to lower blood pressure through dual mechanisms of vasodilation and sodium/fluid reduction.

Micardis Plus combines telmisartan (an angiotensin II receptor blocker) with hydrochlorothiazide (a thiazide diuretic) to lower blood pressure through dual mechanisms of vasodilation and sodium/fluid reduction. Used for Hypertension (essential hypertension in patients requiring combination therapy).

At a glance

Generic nameMicardis plus 80/12.5
SponsorHeart Care Foundation
Drug classAngiotensin II receptor blocker + thiazide diuretic combination
TargetAT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Telmisartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release, thereby reducing peripheral vascular resistance and blood pressure. Hydrochlorothiazide acts as a thiazide diuretic that increases sodium and water excretion, reducing blood volume and further lowering blood pressure. The combination provides synergistic antihypertensive effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Micardis plus 80/12.5

What is Micardis plus 80/12.5?

Micardis plus 80/12.5 is a Angiotensin II receptor blocker + thiazide diuretic combination drug developed by Heart Care Foundation, indicated for Hypertension (essential hypertension in patients requiring combination therapy).

How does Micardis plus 80/12.5 work?

Micardis Plus combines telmisartan (an angiotensin II receptor blocker) with hydrochlorothiazide (a thiazide diuretic) to lower blood pressure through dual mechanisms of vasodilation and sodium/fluid reduction.

What is Micardis plus 80/12.5 used for?

Micardis plus 80/12.5 is indicated for Hypertension (essential hypertension in patients requiring combination therapy).

Who makes Micardis plus 80/12.5?

Micardis plus 80/12.5 is developed and marketed by Heart Care Foundation (see full Heart Care Foundation pipeline at /company/heart-care-foundation).

What drug class is Micardis plus 80/12.5 in?

Micardis plus 80/12.5 belongs to the Angiotensin II receptor blocker + thiazide diuretic combination class. See all Angiotensin II receptor blocker + thiazide diuretic combination drugs at /class/angiotensin-ii-receptor-blocker-thiazide-diuretic-combination.

What development phase is Micardis plus 80/12.5 in?

Micardis plus 80/12.5 is FDA-approved (marketed).

What are the side effects of Micardis plus 80/12.5?

Common side effects of Micardis plus 80/12.5 include Dizziness, Fatigue, Hyperuricemia, Hypokalemia, Headache, Upper respiratory tract infection.

What does Micardis plus 80/12.5 target?

Micardis plus 80/12.5 targets AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter and is a Angiotensin II receptor blocker + thiazide diuretic combination.

Related